HIIFS
MBRX icon

Harel Insurance Investments & Financial Services’s Moleculin Biotech MBRX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27
Closed -$136K – 828
2021
Q1 		$136K Buy
+27
New +$49.5K ﹤0.01% 606

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Harel Insurance Investments & Financial Services's MBRX Position: Q2 2021 in Review

Harel Insurance Investments & Financial Services sold out of Moleculin Biotech (MBRX) in Q2 2021, closing a stake of 27 shares — an estimated $136K sold.

Harel Insurance Investments & Financial Services first reported a position in MBRX in Q1 2021 and held it in 1 quarter. The position peaked at $136K in Q1 2021. 28 funds tracked by Wall St. Rank hold MBRX as of Q2 2021.

  • Harel Insurance Investments & Financial Services reported no remaining Moleculin Biotech position as of Q2 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 27 Moleculin Biotech shares in Q2 2021, an estimated $136K.
  • Harel Insurance Investments & Financial Services first reported a position in Moleculin Biotech in Q1 2021 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Moleculin Biotech position peaked at $136K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2021, filed 26 Jul 2021.